Watson Pharma (WPI) Unit Receives Approval for Generic Lysteda ANDA

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that its subsidiary Watson Laboratories, Inc. – Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda.

Watson intends to begin shipping the product immediately. Lysteda® is indicated for the treatment of cyclic heavy menstrual bleeding. Ferring B.V. has filed lawsuits against Watson, alleging that Watson's ANDA product infringes U.S. Patent Nos. 7,947,739, 8,022,106, and 8,273,795. The litigations remain pending.

For the 12 months ending November 30, 2012, Lysteda had total U.S. sales of approximately $25 million according to IMS Health data.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• EMA Approves MAA for Gilead's (GILD) Sofosbuvir
• UPDATE: Senate Takes Aim at Apple (AAPL); Says Irish Unit Earned $22B, Paid $10M in Taxes
• SolarWinds (SWI) Acquires N-able Technologies for $120M

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?